The validation trial is going to be shorter, sooner and cheaper than I expected. The r&d rebate we get in a few weeks is enough to cover it. great hemorrhagic stroke sensitivity results well above targets and going into the validation trial with a lot of confidence. i think this stock can move very fast when the focus shifts to the financial prospects.
The validation trial is going to be shorter, sooner and cheaper...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.80 |
Change
0.005(0.28%) |
Mkt cap ! $153.9M | |||
| Open | High | Low | Value | Volume |
| $1.78 | $1.83 | $1.76 | $62.42K | 34.83K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $1.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.82 | 10740 | 2 |
View Market Depth
| Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
| EMV (ASX) Chart |